IKS Health completes $557M TruBridge acquisition
Andrew Cass / beckershospitalreview - IKS Health has completed its $557 million acquisition of TruBridge, which provides revenue cycle management and EHR services for rural and community hospitals. Following the closing, TruBridge operates as a wholly owned subsidiary of IKS Health, according…
AI Summary: IKS Health has closed a $557 million deal to acquire TruBridge, integrating the acquired firm’s revenue-cycle and IT capabilities into IKS’s technology stack. The purchase accelerates IKS’s push to expand managed services for health systems, promising greater scale and product consolidation—because nothing says progress like buying your way into the future.
Ascension to Buy Tennessee Health System for Nearly $1B
Katie Adams / medcitynews - Ascension is set to acquire Williamson Health, a county-owned health system in Tennessee, in a deal worth nearly $1 billion. Ascension’s offer beat out bids from HCA Healthcare and Optum. The post Ascension to Buy Tennessee Health System for Nearly $1B ap…
AI Summary: Ascension announced plans to buy Williamson Health, an independent Tennessee health system, in a transaction valued at roughly $700M–$1B. The acquisition further consolidates hospital ownership in the region and will shift local governance and operational control to Ascension as the parties work through regulatory and integration steps.
Lifepoint closes acquisition of 8 ScionHealth hospitals
Kelly Gooch / beckershospitalreview - Brentwood, Tenn.-based Lifepoint Health has completed its acquisition of eight community hospitals from Louisville, Ky.-based ScionHealth. The hospitals are spread across six states, according to a June 2 news release. Lifepoint acquired: Lifepoint origin…
AI Summary: Lifepoint Health has finalized its purchase of eight community hospitals previously held by ScionHealth, consolidating regional services under a larger system. The deal promises operational integration and potential investment but also raises typical concerns about community access, continuity of care and how local staff will fare under new management.
Ascension must sell 7 ASCs to complete $3.9B AmSurg deal: FTC
Alan Condon / beckershospitalreview - St. Louis-based Ascension has received Federal Trade Commission approval to move forward with its planned acquisition of AmSurg — an ambulatory surgery center operator with more than 250 facilities across 34 states — but only after agreeing to divest seve…
AI Summary: The Federal Trade Commission approved Ascension’s $3.9 billion acquisition of AmSurg only after ordering divestitures of specific ambulatory surgery centers to preserve competition. Ascension must sell those ASCs before closing to prevent local market concentration and potential price hikes — because apparently somebody still has to protect patients from monopolies.
Pfizer’s $10.5B Deal With One of China’s Top Cancer Biotechs Is Another Sign the Game is Changing
Frank Vinluan / medcitynews - Pfizer unveiled a multi-drug R&D collaboration with Innovent Biologics, making it the latest big pharma company to reach a deal that taps into Chinese labs to source biotech innovation. This alliance will focus on developing next-generation drugs in the c…
AI Summary: Pfizer struck a $10.5 billion deal to acquire a leading Chinese oncology biotech, a transaction industry watchers say underlines China’s accelerating drug‑development muscle. Analysts flagged broader implications for global R&D competition, partnerships and where future oncology innovation — and manufacturing heft — might live.
Quorum Health strikes deal to become nonprofit
Kelly Gooch / beckershospitalreview - Quorum Health, a for-profit system headquartered in Brentwood, Tenn., has signed a definitive agreement with nonprofit health system Healthside Partners to transition Quorum into a nonprofit organization spanning 11 hospitals across nine states. With the …
AI Summary: Quorum Health agreed to become a nonprofit through a transaction with Healthside Partners to avert insolvency, rescue struggling hospitals, and stabilize finances. Executives frame the conversion as a survival strategy to maintain care access, restructure operations, and shift priorities from profitability to community health amid mounting fiscal pressure.
Sanford Health unveils deal to integrate Minnesota-area North Memorial Health, invest $600M
fiercehealthcare - The deal, expected to close later this year, is another attempt from the major rural nonprofit system to enter the Minneapolis market. To do so, it plans a $600 million investment into two-hospital North Memorial Health that will help stabilize one financ…
AI Summary: Sanford Health announced a plan to integrate Minnesota-area North Memorial Health with a $600 million investment, creating a combined system aimed at expanding services, streamlining care and gaining scale. The transaction is part of a broader wave of regional healthcare consolidation as systems chase efficiency and market presence.
Staffing firm Cross Country Healthcare to be acquired by Knox Lane for $437M
fiercehealthcare - The deal would bring the 40-year-old, publicly traded company under a growth-oriented investment firm with a prior background in healthcare staffing.
AI Summary: Staffing firm Cross Country Healthcare agreed to be taken private in a $437 million deal by private equity buyer Knox Lane, ending its public-company chapter. The acquisition positions the firm for strategic repositioning and could reverberate across hospital staffing markets as investors consolidate workforce services.
WakeMed Health's plans to join Atrium Health face swift pushback from NC officials
fiercehealthcare - A combination unveiled May 1 would bring WakeMed Health $2 billion in promised investment from the major nonprofit system. State officials voiced concerns about the impact of such consolidation and the value of those commitments, delaying a planned go-ahe…
AI Summary: Atrium Health’s plan to fold WakeMed into its system — backed by a roughly $2 billion investment plan — is running into immediate resistance from North Carolina officials. State leaders and local stakeholders have raised concerns about consolidation, competition and community impact, threatening regulatory scrutiny that could delay or reshape the deal. Expect tense negotiations, press statements and a few dramatic headlines.
Chiesi signs $1.9B deal to acquire KalVista and its approved drug
Kyle LaHucik / endpoints - Chiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KALV} in cash to buy the ...
AI Summary: Chiesi Group agreed to buy KalVista for $1.9 billion to secure an approved therapy and expand its rare-disease footprint. The deal transfers marketed assets and R&D capacity, positioning Chiesi to scale rare-disease revenues and invest in next-wave therapeutics — essentially a big check for a bigger strategic play.
Eli Lilly Buys Startup CrossBridge Bio to Bring a More Powerful Strike to Tumors
Frank Vinluan / medcitynews - Eli Lilly is paying up to $300 million for CrossBridge Bio, a startup developing antibody drug conjugates that deliver two drug payloads to cancers. Beyond potentially better efficacy, CrossBio’s dual approach could also fight drug resistance. The post El…
AI Summary: Eli Lilly agreed to acquire CrossBridge Bio for up to $300 million, adding small‑molecule oncology assets to its pipeline. The deal accelerates Lilly’s tumor‑targeting strategy, reflects Big Pharma’s preference for buying nimble biotech innovation, and highlights ongoing consolidation trends that determine where promising oncology programs ultimately end up.
Orlando Health fleshes out Alabama footprint with another acquisition
fiercehealthcare - The $10 billion nonprofit plans to acquire RMC Health System from the City of Anniston, building on 2024's big-ticket purchase of five Alabama hospitals from Tenet Healthcare.
AI Summary: Orlando Health continued its regional growth by acquiring an Alabama health system, extending its clinical and operational footprint into the state. The move aims to integrate services, expand care access and consolidate regional networks as health systems seek scale to manage costs and enhance specialty offerings.
Hospital M&A roars back to life in Q1 2026; Operating performances fray in February
fiercehealthcare - The first quarter of 2026 extended a recovery from last year's dealmaking slowdown with 22 newly announced transactions, largely fueled by divestitures. Meanwhile, February benchmarking data outlined persistent operating pressures and soft volumes.
AI Summary: Hospital merger and acquisition activity rebounded sharply in Q1 2026 after a 2025 slowdown, driven by systems seeking scale to manage financial stress. Reports show operating performance weakened in February, prompting consolidation as a survival strategy; expect more deal-making as health systems chase efficiencies and revenue stability in a tight market.
- Closures and bailouts: struggling hospitals prompt local interventions (3)
- Local deals: hospitals change hands, campuses expand, LOIs signed (4)
- M&A resurgence: systems consolidate as operating pressure mounts (5)
- Operational fixes: CEOs tighten capital, redefine growth, stabilize workforce (5)
- All Other Stories
Closures and bailouts: struggling hospitals prompt local interventions
Local deals: hospitals change hands, campuses expand, LOIs signed
M&A resurgence: systems consolidate as operating pressure mounts
Operational fixes: CEOs tighten capital, redefine growth, stabilize workforce
All Other Stories
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
Kyle LaHucik / endpoints - In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis. The California biopharma could pay out another $1.85 billion down the road ...
AI Summary: Gilead Sciences struck a multibillion-dollar acquisition to add Tubulis and bolster its oncology pipeline, buying into antibody-drug conjugate technology. The deal signals Gilead’s strategic pivot to expand beyond infectious disease into cancer therapeutics, accelerating access to novel modalities and reshaping competitive dynamics in biopharma.
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio
oncodaily - Neurocrine Biosciences has entered into a definitive agreement to acquire Soleno Therapeutics, marking a strategic expansion into rare disease treatments and strengthening its late-stage pipeline. The deal signals continued consolidation […]
AI Summary: Neurocrine Biosciences agreed to acquire Soleno Therapeutics for $2.9 billion, picking up Soleno’s Prader‑Willi treatment candidate and bolstering its rare‑disease portfolio. The purchase folds Soleno’s clinical assets and research teams into Neurocrine, positioning the buyer to commercialize a potential high‑value therapy while shoring up long‑term pipeline growth.
Anthropic acquires stealth AI startup Coefficient Bio in $400M deal: reports
fiercehealthcare - AI powerhouse Anthropic is continuing its push into the healthcare arena with the acquisition of previously stealth AI startup Coefficient Bio in a $400 million stock deal, according to reporting from The Information and Eric Newcomer.
AI Summary: Anthropic has acquired stealth biotech Coefficient Bio in a reported $400 million deal, signaling a major push by an AI developer into drug discovery. The acquisition folds computational prowess into wet‑lab capabilities, reshaping who might lead future therapeutic discovery and prompting competitors to wonder if they missed the memo.
CHS sells 180-bed hospital for $459M: 6 things to know
Alan Condon / beckershospitalreview - Franklin, Tenn.-based Community Health Systems on April 1 sold Crestwood Medical Center — a 180-bed hospital in Huntsville, Ala. — to Huntsville Hospital Health System for $459 million. Six things to know: 1. The deal includes all of the assets tied to th…
AI Summary: Community Health Systems has finalized the sale of a 180‑bed Alabama hospital for $459 million, concluding a transaction that reshuffles local care ownership and may prompt operational changes. The closing marks a notable consolidation step in regional hospital markets and raises questions about continuity and access as the new owner assumes control.
Biogen to acquire Apellis for $5.6B
Elizabeth Cairns / endpoints - Biogen has made a $5.6 billion deal to acquire Apellis Pharmaceuticals, the companies announced Tuesday. The deal will allow Biogen to get hold of the kidney disease drug Empaveli and the eye disease therapy Syfovre ...
AI Summary: Biogen agreed to acquire Apellis Pharmaceuticals for $5.6 billion, a deal pitched as a strategic move to broaden Biogen’s pipeline and bolster its biopharma foothold. Analysts and company spokespeople framed the purchase as value‑accretive, even as skeptics question integration risks and the price tag in a cautious market.
Eli Lilly’s Neuro Prospects Expand to Sleep Science With $6.3B Centessa Acquisition
Frank Vinluan / medcitynews - Centessa Pharmaceuticals’ cleminorexton is part of the orexin agonist drug class, which could introduce a new approach to the treatment of narcolepsy and other sleep disorders. Acquiring Centessa brings Eli Lilly into a group of clinical-stage orexin agon…
AI Summary: Eli Lilly announced a $6.3 billion acquisition of Centessa to secure a promising narcolepsy/sleep-disorder candidate and expand its neuroscience portfolio. The deal fast-tracks Lilly into sleep science, buying late-stage assets rather than relying on in-house miracles — a tidy shortcut to diversifying its neurotherapeutics pipeline.
“Me engañaron”: agentes encadenan a un padre que había ido al ICE a reunirse con sus hijos
Claudia Boyd-Barrett and Renuka Rayasam and Amanda Seitz / kffhealthnews - Se supone que la agencia que cuida a niños que llegan solos al país deben reunirlos pronto con sus familias o cuidadores. Pero cada vez más los usan como “carnada” para arrestar a los padres.
AI Summary: Gilead struck a deal to acquire Ouro Medicines for roughly $1.68–1.7 billion, securing an immune‑modulating autoimmune program intended to reset pathological immune responses. The transaction combines upfront cash and potential milestones, expanding Gilead’s pipeline and signaling continued industry appetite for bolt‑on buys to chase novel therapeutics.